Monitoring Agency Report for the quarter ended March 31, 2026
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Solara Active Pharma Sciences has submitted its Q4 FY26 monitoring report for the Rights Issue completed in May-June 2024. The Rs 446.95 crore rights issue has seen Rs 308.58 crore (69%) deployed so far, with Rs 138.37 crore remaining unutilized. Of the unutilized amount, Rs 134.99 crore is expected to be received in FY27 via a second call, Rs 2.18 crore is pending from the first call, and Rs 1.20 crore lies in the monitoring account. Funds have been allocated for debt repayment (Rs 334.71 crore) and general corporate purposes (Rs 112.24 crore). The monitoring agency confirms no deviation from the stated objects and no unfavorable events affecting project viability.
This is a routine compliance filing with positive confirmation - no deviations in fund utilization means the company is on track with its stated objectives. Shareholders can be reassured that rights issue proceeds are being used as promised, though significant funds remain pending from the second call which will impact debt repayment timeline.